Cargando…

GLP-1 based therapeutics: simultaneously combating T2DM and obesity

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic co...

Descripción completa

Detalles Bibliográficos
Autores principales: Heppner, Kristy M., Perez-Tilve, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367528/
https://www.ncbi.nlm.nih.gov/pubmed/25852463
http://dx.doi.org/10.3389/fnins.2015.00092

Ejemplares similares